Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions

Publication date

2019-12

Authors

Hempenius, M.ISNI 0000000492511755
Groenwold, Rolf H.H.ISNI 0000000394374611
De Boer, AnthoniusISNI 0000000389596105
Klungel, Olaf H.ISNI 0000000390199414
Gardarsdottir, HelgaORCID 0000-0001-5623-9684ISNI 0000000395317045

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

Abstract

PURPOSE: The antiarrhythmic drug amiodarone has a long half-life of 60 days, which is often ignored in observational studies. This study aimed to investigate the impact of different exposure definitions on the association between amiodarone use and the risk of acute pancreatitis. METHOD: Using data from the Dutch PHARMO Database Network, incident amiodarone users were compared to incident users of a different type of antiarrhythmic drug. Eighteen different definitions were applied to define amiodarone exposure, including dichotomized, continuous and categorized cumulative definitions with lagged effects to account for the half-life of amiodarone. For each exposure definition, a Cox proportional hazards model was used to estimate the hazard ratio (HR) of hospitalization for acute pancreatitis. RESULTS: This study included 15,378 starters of amiodarone and 21,394 starters of other antiarrhythmic drugs. Adjusted HRs for acute pancreatitis ranged between 1.21-1.43 for dichotomized definitions of exposure to amiodarone, between 1.13-1.22 for dose definitions (per DDD) and between 0.52-1.72 for cumulative dose definitions, depending on the category. Accounting for lagged effects had little impact on estimated HRs. CONCLUSIONS: This study demonstrates the relative insensitivity of the association between amiodarone and the risk of acute pancreatitis against a broad range of different exposure definitions. Accounting for possible lagged effects had little impact, possibly because treatment switching and discontinuation was uncommon in this population.

Keywords

amiodarone, drug therapy, pancreatitis, pharmacoepidemiology, research design

Citation

Hempenius, M, Groenwold, R H H, de Boer, A, Klungel, O H & Gardarsdottir, H 2019, 'Amiodarone use and the risk of acute pancreatitis : Influence of different exposure definitions', Pharmacoepidemiology and Drug Safety, vol. 28, no. 12, pp. 1563-1571. https://doi.org/10.1002/pds.4851